Procter & Gamble Health Ltd
NSE:PGHL
Procter & Gamble Health Ltd
NSE:PGHL
Price:
4 778.6
INR
-0.64%
Market Closed
Market Cap:
₹79.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Procter & Gamble Health Ltd
NSE:PGHL
|
IN |
|
Citizens Financial Group Inc
NYSE:CFG
|
US |
|
Nerdy Inc
NYSE:NRDY
|
US |
|
Britannia Industries Ltd
NSE:BRITANNIA
|
IN |
|
Dhampur Sugar Mills Ltd
NSE:DHAMPURSUG
|
IN |
|
Suntak Technology Co Ltd
SZSE:002815
|
CN |
|
N
|
National World PLC
LSE:NWOR
|
UK |
|
S
|
Sobute New Materials Co Ltd
SSE:603916
|
CN |
|
H
|
Harbour-Link Group Bhd
KLSE:HARBOUR
|
MY |
|
Estun Automation Co Ltd
SZSE:002747
|
CN |
|
Medibank Private Ltd
ASX:MPL
|
AU |
|
BRD Klee A/S
CSE:KLEE B
|
DK |
|
HT&E Ltd
ASX:HT1
|
AU |
|
Eve Holding Inc
NYSE:EVEX
|
US |
|
D
|
Dermapharm Holding SE
DUS:DMP
|
DE |
|
Schaeffler AG
XETRA:SHA0
|
DE |
|
A
|
Affiliated Resources Corp
OTC:AFFL
|
US |
|
I
|
IDBI Bank Ltd
NSE:IDBI
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
PGHL
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 4 778.6 INR,
Procter & Gamble Health Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PGHL Multiples-Based Value
LOCKED
Multiples Across Competitors
PGHL Competitors Multiples
Procter & Gamble Health Ltd Competitors
Procter & Gamble Health Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Procter & Gamble Health Ltd
NSE:PGHL
|
79.3B INR | 5.9 | 27 | 18.8 | 20.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
